Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 12Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Pancreatic Neuroendocrine Tumor G2 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Acromegaly 1

Interventions

Temozolomide 2Capecitabine 2veliparib 1motesanib diphosphate 1epothilone B 1batifiban 1Sorafenib 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vipoma × Octreotide × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡